https://pharminent.com/strategic-news-watch/strategic-news-watch-july-30-2026/ 2026-07-30T16:21:19Z Pharminent en Strategic News Watch • July 30, 2026 2026-07-30T16:21:16Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-july-29-2026/ 2026-07-30T14:49:42Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • July 29, 2026 2026-07-30T14:49:40Z Blog https://pharminent.com/gsk-cambridge-move-signals-shift-in-drug-scale-up-strategy/ 2026-07-29T20:55:26Z Pharminent en GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy 2026-07-29T20:37:33Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-july-29-2026/ 2026-07-29T20:17:48Z Pharminent en Manufacturing Intelligence • Weekly Digest • July 29, 2026 2026-07-29T20:17:46Z Blog https://pharminent.com/vertex-abcellera-partner-on-next-generation-t-cell-engagers-for-autoimmune-disease/ 2026-07-29T20:38:12Z Pharminent en Vertex, AbCellera Partner on Next-Generation T-Cell Engagers for Autoimmune Disease 2026-07-29T20:01:18Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-29-2026/ 2026-07-29T19:30:45Z Pharminent en Strategic News Watch • July 29, 2026 2026-07-29T15:42:39Z Blog https://pharminent.com/leqembi-sales-grow-again-after-subcutaneous-approvals/ 2026-07-30T17:58:38Z Pharminent en Leqembi sales grow again after subcutaneous approvals 2026-07-29T11:53:51Z Blog https://pharminent.com/eisai-and-core-biomedicine-agree-on-global-licence-for-oncology-pipeline/ 2026-07-30T17:56:09Z Pharminent en Eisai and CORE Biomedicine agree on global licence for oncology pipeline 2026-07-29T08:37:33Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-july-28-2026/ 2026-07-28T21:27:59Z Pharminent en Oncology Intelligence Digest • July 28, 2026 2026-07-28T21:27:56Z Blog https://pharminent.com/gsk-unveils-three-year-restructuring-to-fund-late-stage-rd-ahead-of-patent-cliff/ 2026-07-28T23:17:32Z Pharminent en GSK Unveils Three-Year Restructuring to Fund Late-Stage R&D Ahead of Patent Cliff 2026-07-28T20:25:12Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-28-2026/ 2026-07-28T16:01:53Z Pharminent en Strategic News Watch • July 28, 2026 2026-07-28T16:01:50Z Blog https://pharminent.com/altimmune-rises-as-glp-1-gip-drug-curbs-heavy-drinking-in-mid-stage-study/ 2026-07-30T17:57:11Z Pharminent en Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study 2026-07-28T12:54:07Z Blog https://pharminent.com/gsk-to-quit-stevenage-for-new-rd-site-in-cambridge/ 2026-07-30T17:57:28Z Pharminent en GSK to quit Stevenage for new R&D site in Cambridge 2026-07-28T12:53:53Z Blog https://pharminent.com/argenx-signs-agreement-to-buy-forte-biosciences-for-2-2bn-2/ 2026-07-28T18:24:05Z Pharminent en Argenx signs agreement to buy Forte Biosciences for $2.2bn 2026-07-28T08:35:41Z Blog